INS and COVID-19: In COVID-19, ACE2 dysregulation by SARS-CoV-2 leads to marked elevation of vasoconstrictor AngII with a reduction in the vasodilator Ang1-7 (Figure 1), which per se leads to pancreatic β-cell dysfunction, inhibition of insulin secretion, and hyperglycemia, which might be transient even in non-DM patients (20).